Avalo Therapeutics, Inc. (AVTX)
AVTX moved a median of +0.39% 30 minutes after news, and -0.64% by the close. How AVTX actually reacts to news — the realized, point-in-time move the market made, measured across 371 labeled events over the last three years with zero look-ahead.
AVTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 346 |
| 30-min | +0.39% | 57% | 359 |
| 60-min | 0.00% | 49% | 367 |
| to close | -0.64% | 45% | 370 |
| Middle 50% of AVTX reactions | -1.58% to +2.49% |
|---|---|
| Median reaction (30-min) | +0.39% |
| Measured reactions | 371 |
Half of all Avalo Therapeutics, Inc. news events land between -1.58% and +2.49% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AVTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 44 | -0.53% | 30% | +0.83% |
| Rating reiterations | 29 | -0.93% | 41% | -2.17% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how AVTX ranks against every other measured name →
That’s how AVTX usually reacts — get an email when it moves on news →Email me when AVTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AVTX's baseline. Nothing else.
Recent AVTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.47% | -2.98% | |
| Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress | Press release | GlobeNewswire | +0.34% | -6.71% | |
| Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.32% | +3.68% | |
| Avalo Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -2.07% | -2.91% | |
| Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates | Press release | GlobeNewswire | +4.39% | +4.64% | |
| Form 10-Q Avalo Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.39% | +4.64% | |
| Form 8-K Avalo Therapeutics, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +4.39% | +4.64% | |
| Form EFFECT Avalo Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.56% | -3.40% | |
| Avalo Therapeutics to Participate in the BTIG Biotechnology Conference | Press release | GlobeNewswire | +1.83% | -2.10% | |
| Form S-3 Avalo Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.26% | -6.38% | |
| Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum | Press release | GlobeNewswire | -0.06% | -5.64% | |
| Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes | Press release | GlobeNewswire | -0.06% | +1.11% | |
| Avalo Therapeutics Appoints Ron Philip to Board of Directors | Press release | GlobeNewswire | +2.50% | +6.26% | |
| Form 8-K Avalo Therapeutics, Inc. For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | +2.50% | +6.26% | |
| Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1ß Antibody | Press release | GlobeNewswire | -1.10% | -1.78% | |
| Form 8-K Avalo Therapeutics, Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | -1.10% | -1.78% | |
| Form 8-K Avalo Therapeutics, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | -2.73% | |
| Form 8-K Avalo Therapeutics, Inc. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +0.54% | -0.23% | |
| Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.30% | -3.32% | |
| Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates | Press release | GlobeNewswire | -1.86% | -1.78% | |
| Form 10-Q Avalo Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.86% | -1.78% | |
| Form 8-K Avalo Therapeutics, Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -1.86% | -1.78% | |
| Form 8-K Avalo Therapeutics, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +1.44% | +2.56% | |
| Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa | Press release | GlobeNewswire | -3.28% | -4.68% | |
| Avalo Therapeutics Announces Pricing of $375 Million Public Offering | Press release | GlobeNewswire | -3.28% | -4.68% | |
| Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -3.28% | -4.68% | |
| Form 8-K Avalo Therapeutics, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -3.28% | -4.68% | |
| Avalo Therapeutics Purchases Optional Milestone Buyout | Press release | GlobeNewswire | +3.30% | -9.69% | |
| Form 8-K Avalo Therapeutics, Inc. For: Apr 26 | SEC filing · Form 8-K | SEC EDGAR | +3.30% | -9.69% | |
| Form ARS Avalo Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.79% | -1.48% | |
| Form DEF 14A Avalo Therapeutics, Inc. For: Apr 10 | SEC filing · Form DEF | SEC EDGAR | +1.79% | -1.48% | |
| Form DEFA14A Avalo Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.79% | -1.48% | |
| Form 8-K Avalo Therapeutics, Inc. For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | -0.69% | +1.46% | |
| Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates | Press release | GlobeNewswire | +1.19% | +0.60% | |
| Form 10-K Avalo Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.19% | +0.60% | |
| Form 8-K Avalo Therapeutics, Inc. For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +1.19% | +0.60% | |
| Form S-8 Avalo Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.19% | +0.60% | |
| Avalo Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.39% | +9.46% | |
| Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.94% | +7.25% | |
| Avalo Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.37% | -10.36% | |
| Form EFFECT Avalo Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +2.06% | +6.49% | |
| Form 8-K Avalo Therapeutics, Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.82% | -2.57% | |
| Form S-3 Avalo Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.38% | -1.28% | |
| Form 8-K Avalo Therapeutics, Inc. For: Dec 02 | SEC filing · Form 8-K | SEC EDGAR | -0.47% | -6.48% | |
| Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.66% | +7.40% | |
| Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates | Press release | GlobeNewswire | +3.98% | -2.53% | |
| Form 10-Q Avalo Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.98% | -2.53% | |
| Form 8-K Avalo Therapeutics, Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +3.98% | -2.53% | |
| Form S-8 Avalo Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +3.98% | -2.53% | |
| Avalo Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.94% | -7.39% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AVTX section they belong to.
Where else AVTX is measured.
AVTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Avalo Therapeutics, Inc.'s median reaction calculated?
Every labeled AVTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 371 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 57% of AVTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AVTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.